Moderna shares are down on Monday, pulling back following a recent report highlighting its latest cancer trial results.
Shares of Moderna MRNA rose 13% in the past week after the company announced preliminary sales for the full-year 2025, as ...
Moderna is down 80% from its 52-week high as revenues continue to fall and the new RSV vaccine has performed poorly. MRNA has guided for 2025 revenues of $1.5B-$2.5B which doesn't seem to have helped ...
Moderna (NASDAQ:MRNA) Stock, Option Chain Option chain shows key data for Moderna's stock options at various strike prices and expiration dates. Traders use this information to analyze potential ...
Zacks Investment Research on MSN
MRNA & MRK's Personalized Cancer Therapy Delivers Strong 5-Year Data
Shares of Moderna MRNA were up 15.8% on Jan. 21, after the company and its partner Merck MRK announced positive median ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results